Barclays lowered the firm’s price target on Omada Health (OMDA) to $17 from $22 and keeps an Overweight rating on the shares. The firm sees the company posting 20% revenue growth in Q4.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- OMDA Upcoming Earnings Report: What to Expect?
- Omada Health expands platform to include cholesterol management
- Omada Health: Sentiment-Driven Sell-Off Creates Compelling Entry Point Amid Accelerating Growth and Limited Policy Risk
- Omada Health: Strong 2025 Finish, GLP-1 Tailwinds, and Attractive 2026 Valuation Upside Support Reiterated Buy Rating
- Omada Health price target lowered to $26 from $29 at Goldman Sachs